Fast Five Quiz: Radiation Therapy for Metastatic and Advanced Prostate Cancer

Evelyn S. Marienberg, MD


November 08, 2022

While the exact prevalence of oligometastatic disease is unknown, the estimated prevalence may range between 30% and 50%. Müller and colleagues identified oligometastatic recurrent prostate cancer in up to 30% of patients on the basis of the presence of a minimum of three metastatic lesions and prostate-specific membrane antigen PET to identify lesions. Labri and colleagues, however, found that 50% of patients who underwent whole body MRI with diffusion-weighted imaging for prostate cancer monitoring had three or fewer metastatic sites at diagnosis with metastatic disease.

Learn more about radiation treatment of metastatic and advanced prostate cancer.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.